

# Pre-emptive, OCT guided angioplasty of vulnerable, intermediate coronary lesions: a randomized trial, the 'PECTUS' Trial

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Recruiting
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON26010

### Source

Nationaal Trial Register

### Brief title

PECTUS

### Health condition

Coronary artery disease; vulnerable plaque

## Sponsors and support

**Primary sponsor:** VU University Medical Center

**Source(s) of monetary or material Support:** Abbott Vascular, St. Jude Medical

## Intervention

## Outcome measures

### Primary outcome

A composite of major adverse cardiovascular events (all cause mortality, non-fatal

myocardial infarction (STEMI or NSTEMI), or unplanned revascularization) at one year follow-up

### **Secondary outcome**

The same composite at 2 and 5 years

## **Study description**

### **Study objective**

Stenting with a bioabsorbable vascular scaffold of intermediate, vulnerable coronary lesions in patients with residual non-obstructive CAD after myocardial infarction will prevent future Major Adverse Cardiac Events (MACE)

### **Study design**

1, 2 and 5 years

### **Intervention**

After inclusion, patients will undergo coronary CT and OCT to determine if the residual stenosis is vulnerable. In case of vulnerable plaques at OCT, patients will be randomized to PCI with BVS placement or to conservative (optimal medical) therapy.

## **Contacts**

### **Public**

Department of Cardiology, VU University<br>  
de Boelelaan 1117  
Niels Royen, van  
Amsterdam 1081 HV  
The Netherlands  
+31 (0)20 4442244

### **Scientific**

Department of Cardiology, VU University<br>  
de Boelelaan 1117  
Niels Royen, van  
Amsterdam 1081 HV  
The Netherlands  
+31 (0)20 4442244

# Eligibility criteria

## Inclusion criteria

- Informed consent must be obtained
- Patients with STEMI or NSTEMI and residual, non-obstructive CAD, with the possibility of plaque vulnerability.
- The coronary lesion must be suitable for PCI with a commercially available BVS.

## Exclusion criteria

- Refusal or inability to provide informed consent.
- < 18 years of age
- Previous CABG.
- Indication for revascularization by CABG.
- Target vessel diameter < 2,5 mm or >4.0 mm
- Anatomy or lesions unsuitable for OCT catheter crossing or imaging (aorta-ostial lesions, small diameter segment, severe calcifications)
- Anatomy unsuitable for BVS placement (left main, bifurcation stenting, sidebranch (> 2 mm) involvement).
- Target lesion is instent restenosis
- Target lesion is chronic total occlusion

- Severe kidney disease defined as an eGFR < 30 ml/min.
- Pregnancy.

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)
Control:	Active

### Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	04-03-2016
Enrollment:	500
Type:	Anticipated

## Ethics review

Positive opinion	
Date:	08-12-2015
Application type:	First submission

## Study registrations

### Followed up by the following (possibly more current) registration

ID: 43561  
Bron: ToetsingOnline  
Titel:

4 - Pre-emptive, OCT guided angioplasty of vulnerable, intermediate coronary lesions ... 25-05-2025

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL4177
NTR-old	NTR5590
CCMO	NL55011.029.15
OMON	NL-OMON43561

## Study results